Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03294330 · ClinicalTrials.gov registry record · Phase 3
SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer
A Phase 3 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
NCT03294330 is a Phase 3 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 35 participants.
The verdict
NCT03294330, a Phase 3 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
Study Summary
The objective of this study is to determine if fluorescence lymphangiography can be used alone to localize sentinel nodes in patients with melanoma or breast cancer. The hypothesis is that sentinel nodes can be identified using only indocyanine green (ICG) and fluorescence lymphangiography, without the need for technetium99 and a gamma probe.
Interventions
- DRUG IC-Green KIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-10-11 |
| Est. Completion | 2021-11-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03294330
The ClinicalTrials.gov registry entry for NCT03294330 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IC-Green KIT is the first listed.
NCT03294330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03294330 about?
NCT03294330 is a clinical study titled "SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer". The objective of this study is to determine if fluorescence lymphangiography can be used alone to localize sentinel nodes in patients with melanoma or breast cancer. The hypothesis is that sentinel nodes can be identified using only indocyanine green (ICG) and fluorescence lymphangiography, without ...
What is the current status of trial NCT03294330?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2017-10-11. Estimated completion is 2021-11-02.
What interventions are being tested in trial NCT03294330?
The interventions under investigation include: IC-Green KIT (DRUG).
Who is sponsoring clinical trial NCT03294330?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.